German biotech company MorphoSys buys US rival for $1.7B
Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival Constellation Pharmaceuticals Inc. in a deal valuing the biotech company at $1.7 billion.
- Next story France widens COVID vaccine drive to 12 to 18-year-olds
- Previous story Vaccine protection may diminish need for yearly boosters
Explore more
- Closer to human: Mouse model more accurately reproduces fatty liver disease
Human non-alcoholic fatty liver disease (NAFLD) is a little-understood condition that significantly... - Better-fitting face masks greatly improve COVID-19 protection
Even the best face masks work only as well as their fit. - Joe Rogan wades into the anti-vaccination narrative on his Spotify podcast
Joe Rogan, one of the world’s highest paid and most popular podcast... - S. African COVID variant better at bypassing Pfizer/BioNTech jab: Israeli study
The South African coronavirus variant is better at “breaking through” the defences... - Mobvoi TicWatch GTH review: Worse than just an Apple Watch knock-off
Even at $80, the Mobvoi TicWatch GTH isn’t a recommended purchase. - Everything we know about Call of Duty: Vanguard
They’ve managed to keep things mostly under wraps, but here’s everything we... - South Korea’s dangerous ghost doctors are putting plastic surgery patients’ lives at risk
Weak regulations allow unqualified medics to secretly substitute for star plastic surgeons,... - Stem cell therapy promotes recovery from stroke and dementia in mice
A one-time injection of an experimental stem cell therapy can repair brain... - The world doesn’t have enough computer chips. That’s bad news for you
In the market for a new car, smartphone or washing machine this... - 2021 French Open: What to Watch on Wednesday
Novak Djokovic, Rafael Nadal and Iga Swiatek all feature on the second...